- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT02318563
Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Participants With Inadequately Controlled Dravet Syndrome
A Multicenter, Randomized, Double-blind, Placebo- Controlled, Interventional Study to Assess the Safety and Efficacy of Pharmaceutical Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Subjects With Inadequately Controlled Dravet Syndrome
This Phase 3 study will enroll participants diagnosed with Dravet Syndrome (DS) who are still experiencing at least one tonic-clonic, clonic, and/or focal seizures with motor components (FSMC) per week, despite ongoing treatment with up to three antiepileptic drugs (AEDs), and meet the other inclusion/exclusion criteria.
Following a 28-day baseline period, participants will begin an 84-day treatment period. Participants will be assigned to receive twice-daily doses of placebo or cannabidiol oral solution at the highest dose determined to be safe in a previous trial.
Following study completion, all participants will be invited to receive Cannabidiol Oral Solution in an open label extension study (under a separate protocol).
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Fase
- Fase 3
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Meets protocol-specified criteria for qualification and contraception, including clinical diagnosis of refractory DS and onset of seizures according to protocol-specified criteria
- Is able to speak and understand the language in which the study is being conducted, is able to understand the procedures and study requirements and has voluntarily signed and dated an informed consent form approved by the Institutional Review Board before the conduct of any study procedure
- In the opinion of the Investigator, the subject and/or parent(s)/caregiver(s) are able to keep accurate seizure diaries and the participant is able to take study drug and comply with the protocol, including dosing, medications and diet
Exclusion Criteria:
- Medical history is outside protocol-specified parameters
- Clinically significant history of allergic reactions or significant sensitivities to cannabinoids or to any of the other ingredients in the study drug
- Inadequate supervision by parents or guardians
- History or current use of dietary supplements, drugs or over-the counter medications outside protocol-specified parameters
- Signs, symptoms or history of any condition that, per protocol or in the opinion of the investigator, might compromise: 1) the safety or well-being of the participant or study staff; 2) the safety or well-being of the participant's offspring (such as through pregnancy or breast-feeding); 3) the analysis of results
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Tredobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: Cannabidiol oral opløsning
Deltagerne vil modtage cannabidiol oral opløsning i en passende dosis (ikke højere end 40 mg/kg/dag) bestemt af data fra et tidligere forsøg.
Den samlede daglige dosis vil blive indgivet i doser to gange dagligt med ca. 12 timers mellemrum.
|
An oral solution containing pharmaceutical grade cannabidiol (nonplant-based)
|
Placebo komparator: Placebo løsning
Deltagerne vil modtage matchende placeboopløsning indgivet to gange dagligt med ca. 12 timers mellemrum.
|
A matching oral solution containing no cannabidiol
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
Percent change in the frequency of tonic-clonic, clonic, and focal seizures with motor components
Tidsramme: Data point for observation period to data point for treatment period Weeks 9 through 12
|
Data point for observation period to data point for treatment period Weeks 9 through 12
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
---|---|
Percent change from baseline in the severity of tonic-clonic, clonic, and focal seizures with motor components
Tidsramme: Data point for observation period to data point for treatment period Weeks 9 through 12
|
Data point for observation period to data point for treatment period Weeks 9 through 12
|
Percent change from baseline in the duration of tonic-clonic, clonic, and focal seizures with motor components
Tidsramme: Data point for observation period to data point for treatment period Weeks 9 through 12
|
Data point for observation period to data point for treatment period Weeks 9 through 12
|
Percent change from baseline in the frequency of all seizure activity independent of seizure type
Tidsramme: Data point for observation period to data point for treatment period Weeks 9 through 12
|
Data point for observation period to data point for treatment period Weeks 9 through 12
|
Ændring fra baseline i forælder(e)/plejer(e) Clinical Global Impressions of Improvement (CGI-I)
Tidsramme: Datapunkt for observationsperiode til datapunkt for behandlingsperiode Uge 9 til 12
|
Datapunkt for observationsperiode til datapunkt for behandlingsperiode Uge 9 til 12
|
Ændring fra baseline i forælder(e)/plejer(e) Clinical Global Impressions of Severity (CGI-S)
Tidsramme: Datapunkt for observationsperiode til datapunkt for behandlingsperiode Uge 9 til 12
|
Datapunkt for observationsperiode til datapunkt for behandlingsperiode Uge 9 til 12
|
Ændring fra baseline i Investigator CGI-I
Tidsramme: Datapunkt for observationsperiode til datapunkt for behandlingsperiode Uge 9 til 12
|
Datapunkt for observationsperiode til datapunkt for behandlingsperiode Uge 9 til 12
|
Ændring fra baseline i Investigator CGI-S
Tidsramme: Datapunkt for observationsperiode til datapunkt for behandlingsperiode Uge 9 til 12
|
Datapunkt for observationsperiode til datapunkt for behandlingsperiode Uge 9 til 12
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Studieleder: Neha Parikh, INSYS Therapeutics Inc
Datoer for undersøgelser
Studer store datoer
Studiestart (Forventet)
Primær færdiggørelse (Forventet)
Studieafslutning (Forventet)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- INS011-14-025
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Dravet syndrom
-
Riphah International UniversityAfsluttet
-
Riphah International UniversityAfsluttet
-
Shaare Zedek Medical CenterUkendtPræmenstruelt syndrom - PMS
-
Esra ÖZERKTO Karatay UniversityRekrutteringEffekten af aromaterapiapplikation med bergamot og grapefrugt æteriske olier på PMS (Aromatherapy)Præmenstruelt syndrom - PMSKalkun
-
Brian JonasNational Cancer Institute (NCI); Celgene; Pharmacyclics LLC.AfsluttetTidligere behandlet myelodysplastisk syndrom | Myelodysplastisk syndrom | Terapi-relateret myelodysplastisk syndrom | Sekundært myelodysplastisk syndrom | Refraktært højrisiko myelodysplastisk syndromForenede Stater
-
Hrain Biotechnology Co., Ltd.Shanghai Changzheng HospitalAktiv, ikke rekrutterendePOMES syndrom | Tilbagefaldende og refraktær POMES-syndromKina
-
Riphah International UniversityRekrutteringNedre kors syndromPakistan
-
Foundation University IslamabadRekruttering
-
University of CalgaryUkendtNefrotisk syndrom hos børn | Nefrotisk syndrom, minimal ændring | Nefrotisk syndrom, idiopatiskCanada
-
University of California, Los AngelesBoston Children's Hospital; Duke University; Children's Hospital Medical...RekrutteringBohring-Opitz syndrom | ASXL1 genmutation | Shashi-Pena syndrom | ASXL2-genmutation | Bainbridge-Ropers syndrom | ASXL3 genmutationForenede Stater
Kliniske forsøg med Cannabidiol Oral Solution
-
SocraTec R&D GmbHSocraMetrics GmbH; Glatt Pharmaceutical Services GmbH & Co. KGAfsluttetSammenlignende biotilgængelighedTyskland
-
Rabin Medical CenterUkendtPode versus værtssygdomIsrael
-
Colorado State UniversityInstitute of Cannabis ResearchAfsluttet
-
Radius Pharmaceuticals, Inc.AfsluttetFravær i barndommen EpilepsiForenede Stater
-
INSYS Therapeutics IncAfsluttetSpasmer, InfantilForenede Stater
-
University of Colorado, DenverAktiv, ikke rekrutterendeAutismespektrumforstyrrelseForenede Stater
-
MultiCare Health System Research InstituteIkke længere tilgængeligRefraktær epilepsi
-
Radius Pharmaceuticals, Inc.Benuvia Therapeutics Inc.AfsluttetFravær i barndommen EpilepsiForenede Stater
-
The Methodist Hospital Research InstituteRekrutteringRotator Cuff Skader | Skulder slidgigtForenede Stater
-
Medical University of South CarolinaRekruttering